Endocyte, Inc. (NASDAQ:ECYT) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

A number of other research firms also recently commented on ECYT. Zacks Investment Research upgraded Endocyte from a “sell” rating to a “hold” rating in a report on Thursday, November 9th. Wedbush upgraded Endocyte from a “neutral” rating to an “outperform” rating and increased their price target for the company from $2.00 to $7.00 in a report on Tuesday, October 3rd. Finally, Cowen and Company reiterated a “hold” rating on shares of Endocyte in a report on Monday, October 2nd.

Endocyte (NASDAQ ECYT) opened at $4.72 on Tuesday. Endocyte has a twelve month low of $1.17 and a twelve month high of $6.55.

Endocyte (NASDAQ:ECYT) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). The firm had revenue of $0.03 million for the quarter. Endocyte had a negative return on equity of 38.91% and a negative net margin of 82,235.72%. The firm’s revenue was up .0% on a year-over-year basis. During the same period last year, the firm posted ($0.21) EPS. equities analysts expect that Endocyte will post -1.24 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/endocyte-inc-ecyt-rating-lowered-to-sell-at-valuengine/1706585.html.

In other news, insider Philip S. Low acquired 5,600 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was bought at an average cost of $4.84 per share, with a total value of $27,104.00. Following the transaction, the insider now directly owns 283,005 shares in the company, valued at approximately $1,369,744.20. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 14.86% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. FMR LLC lifted its position in shares of Endocyte by 0.9% during the second quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock worth $5,310,000 after purchasing an additional 31,168 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Endocyte by 1,064.3% during the second quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock worth $646,000 after purchasing an additional 393,975 shares during the last quarter. Renaissance Technologies LLC lifted its position in shares of Endocyte by 284.4% during the first quarter. Renaissance Technologies LLC now owns 192,561 shares of the biopharmaceutical company’s stock worth $495,000 after purchasing an additional 142,461 shares during the last quarter. Parametric Portfolio Associates LLC lifted its position in shares of Endocyte by 57.8% during the first quarter. Parametric Portfolio Associates LLC now owns 162,329 shares of the biopharmaceutical company’s stock worth $417,000 after purchasing an additional 59,454 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Endocyte by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 143,552 shares of the biopharmaceutical company’s stock worth $369,000 after purchasing an additional 6,469 shares during the last quarter. 25.47% of the stock is owned by institutional investors.

Endocyte Company Profile

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.